HOME >> BIOLOGY >> NEWS
JCI Table of Contents, March 14, 2003

ard@cochin.inserm.fr">boitard@cochin.inserm.fr

View the PDF of this article at: https://www.the-jci.org/press/16584.pdf

Cathepsin S promotes atherosclerosis

Remodeling of the ECM contributes to atherosclerosis at multiple stages, and several lines of evidence have implicated the elastolytic cathepsins S (Cat S) and K. Seeking direct evidence for a role of Cat S, Guo-Ping Shi and colleagues crossed mice lacking Cat S with atherosclerosis-prone LDL receptordeficient mice. They found (pages 897906) that the double mutants -- when fed a high-cholesterol diet -- had an attenuated response: atherosclerosis was reduced by more than 50% after 12 weeks on an atherogenic diet, and by 30% after 26 weeks. While this study does not reveal the mechanism by which Cat S contributes to atherogenesis, it does suggest several possible modes of action and underscores the possibility that Cat S may serve as a therapeutic target in arterial diseases.

CONTACT:
Guo-Ping Shi
University of California, San Francisco
Surge 203, Box 0911
90 Medical Center Way
San Francisco, CA 94143
USA
Phone 1-415-514-1208
Fax 1-415-476-9749
E-mail: gpshi@itsa.ucsf.edu

View the PDF of this article at: https://www.the-jci.org/press/14915.pdf

Stem cells mobilized by crisis

Sickle cell disease affects 150 million people worldwide. The only curative therapy is hematopoietic stem cell transplantation. Because of the limited number of matched donors and the toxicity associated with allogeneic transplants, various gene therapy approaches in autologous stem cells are under development. Encouraged by the observation that sickle cell patients have increased numbers of cells expressing stem
'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
14-Mar-2003


Page: 1 2 3 4 5 6 7

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, 1 October, 2003
5. JCI Table of Contents, September 15, 2003
6. JCI Table of Contents
7. JCI Table of Contents, 15 August 2003
8. JCI Table of Contents, May 1, 2003
9. JCI Table of Contents, April 1, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... 21, 2017 Der weltweite Biobanking-Sektor ... Nach einem Gespräch mit mehr als 50 Vertretern aus verschiedenen ... überwinden gilt, um diese Prognose zu realisieren. ... Zu ... der finanziellen Mittel für die Biobank, die Implementierung Zeit ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... Mass. , March 24, 2017 Agenus ... of immune checkpoint antibodies and cancer vaccines, today announced ... The 7 th  Annual William Blair and Maidstone Life ... Space Alexandria Center in New York, NY ... March 29 at 9:40 am: Robert ...
(Date:3/23/2017)... ... 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking ... for companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 ... increasing popularity is due to its new team building format, a way for teams to ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics (OTCQB: ... personalized immune therapies for solid tumor cancers, today ... million financing it announced last Friday, March 17, ... several institutional investors securities totaling 28,843,692 shares, comprised ... and 10,000,000 shares of Class C Warrants pre-funded ...
(Date:3/23/2017)... , March 23, 2017  GlobeImmune, Inc. today announced ... the sale of 12,835,490 shares of its common stock ... of companies. In connection with the sale of its common ... cash and issue to GlobeImmune 200,000 shares, an estimated ... "We are pleased to enter into this ...
Breaking Biology Technology:
Cached News: